News & Events
NASHVILLE (Tuesday, June 13, 2017) – Tennessee Gov. Bill Haslam, Department of Economic and Community Development Commissioner Bob Rolfe and PathGroup officials announced today that the pathology and clinical laboratory services company will undertake a major expansion in Middle Tennessee.
Please Click HERE to see the full release.
On June 5, 2017, PathGroup’s clinical laboratory experienced an analytical event on one of the two general chemistry analyzers that caused a negative bias of calcium levels for those test processed on the affected instrument.
For more Information, CLICK HERE
In an ongoing effort to protect the privacy of our shared patients’ protected health information, PathGroup has strengthened our security measures. Beginning Monday,June 5, 2017, all PathGroup electronic client systems including PathConnect, PathGroup Mobile, Result Review, PathSupply and AutoPrint will have a new Single Sign-On system that will strengthen the authentication access. PathGroup’s new password procedures are required by all users.
For more information, please CLICK HERE
Effective April 26, 2017 when completing an Advanced Beneficiary Notice (ABN) in PathConnect, the person responsible for collecting and submitting the ABN will now be prompted to provide a signature upon completion.
For more information, CLICK HERE
Beginning June 5, 2017, all PathGroup electronic client systems including PathConnect, PathGroup Mobile, Result Review, PathSupply and AutoPrint will have a new Single Sign-On system that will strengthen the authentication access. All users will need to comply with PathGroup’s password policies, including requiring users to reset passwords every 60 days.
For More Information CLICK HERE
Brentwood, TN – (Thursday, February 16, 2017) – PathGroup, one of the largest private providers of pathology and laboratory services in the Unites States, is pleased to announce that Pranil K. Chandra, DO, FCAP, FASCP, Vice President and Chief Medical Officer and Medical Director, Genomic and Clinical Pathology Services at PathGroup, will speak at the 2017 Molecular Medicine Tri-Conference in San Francisco, CA on Monday, February 20, 2017.
Dr. Chandra’s session “Garnering Payer Support for Genomic Profiling by Demonstrating Clinical Utility” will review PathGroup’s experience with certain payers in garnering appropriate reimbursement for genomic profiling. In addition, he will review how to demonstrate clinical utility through illustrative examples highlighting diagnostic, prognostic, and/or therapeutic utility across hematologic and solid tumor malignancies.
For more information on the 2017 Molecular Medicine Tri-Conference please visit, http://www.triconference.com
PathGroup is pleased to announce the release of SmartGenomics™ Complete, a pan cancer assay encompassing 160 cancer related genes, 126 gene fusions and whole genome copy number changes via cytogenomic array.
Also included in this major release are five new solid tumor disease specific profiles for use at diagnosis of various malignancies especially for metastatic, aggressive and/or high grade tumors in the following cancer types: Bladder, Breast, Gynecological (including ovarian carcinoma), Prostate and Sarcoma. Additionally, two new hematologic malignancy profiles have been introduced for myeloid neoplasms and lymphoid neoplasms respectively.
Existing SmartGenomics Profiles have also been improved to include the latest relevant assays such as PDL-1 for NSCLC, Her2 for colorectal cancer, gene fusions for thyroid carcinoma and neurological malignancies, copy number support for melanoma, plus other clinically supported additions. Additional information including the genes of interest, fusion partners and profile breakdowns are available by contacting Oncology Customer Support at OncologySupport@pathgroup.com.
Multiple benefits of high-throughput sequencing (commonly referred to as Next-Generation Sequencing or NGS) include: smaller input DNA requirements, greater sensitivity/specificity, advanced bioinformatics processing and rapid turn-around time.
Click HERE for more information.
– Enhanced cancer data and reporting standards for state cancer registries enable structured, real-time, data-driven decision making for cancer treatment specialists and patients
BRENTWOOD, Tenn., (Nov. 29, 2016) – PathGroup, one of the largest private providers of anatomic pathology and clinical lab services in the U.S., today announced a new partnership with the Centers for Disease Control and Prevention (CDC) and the California Department of Public Health that standardizes nationwide state cancer registry data and reporting, enabling physicians, surgeons and researchers to make data-driven treatment decisions with real-time information and analyses.
For Full Release, CLICK HERE
Brentwood, TENN – (November 11, 2016) – PathGroup, one of the largest private providers of pathology services in the Unites States, is pleased to be recognized by The Centers for Disease Control and Prevention (CDC) as the first national laboratory in the United States to standardize and structure cancer pathology and biomarker data reporting from its laboratory information system (LIS) to all state cancer registries.
PathGroup implemented standardized reporting in its proprietary system using the electronic Cancer Checklists (eCC) published by the College of American Pathologists (CAP). State cancer registries across the country will now electronically receive accurate and near real time cancer data.
Click Here to read the entire release from the CDC.
Dr. Pranil K. Chandra, Assistant Vice President and Medical Director of Molecular Pathology and Genomic Medicine Services at PathGroup, has co-authored a publication titled “The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology”.
The Association of Molecular Pathology (AMP) report addresses the challenges in defining the clinical utility of molecular diagnostics for inherited disease and cancer, including molecular diagnostic procedures used for diagnosis, prognosis, risk assessment, prediction of future disease, and monitoring and selection of therapies of disease in patients. The report puts forth clinical utility definitions that appropriately recognize the contribution and value of molecular diagnostic testing to improve patient care.
The report has been released online ahead of publication in the September 2016 issue of The Journal of Molecular Diagnostics. Click Here to read the full manuscript.
